A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Rituximab (Primary) ; Venetoclax (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- 03 Jul 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 03 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
- 30 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.